CBD: it spans product categories, retail channels, regulatory landscapes – and even species. Last month’s webinar covered the current cannabinoid market as it relates to pain management as well as pet care, both within the dispensary channel (CBD from marijuana) and in the general retail market (hemp-derived CBD). While pain management and pet care might seem like disparate angles from which to talk about cannabinoids, they actually do have some common ground. The wellness market is booming, as consumers’ approach to health care shifts; similarly, the pet industry has grown consistently as pets take on an increasingly heightened role in the American household. Both cannabinoid-based pain and pet products cross retail channels, with availability in medical and adult-use dispensaries as well as across general market retail channels. And, across pain management and pet care, cannabinoid-based products are a welcome supplement (or alternative) to other forms of medical or wellness-based solutions. Here we’ll look at some of the main takeaways from the webinar – but for the full story, you can watch the presentation and download the deck here.
As cannabis products and delivery systems continue to evolve, infused beverages are rapidly moving to the forefront– most recently marked by the announced partnership between Arizona Beverages and Dixie Brands. As of September 1, 2019, BDS Analytics market data reports 107 beverage brands in the legal dispensary channel (up from 69 in Q2 of 2018) across CA, CO, OR, AZ, and NV and BDS Analytics predicts beverage sales in the regulated dispensary channel to reach $1 billion by 2022. Here are the Top 5 canna-beverage facts from BDS Analytics: